Download PDF
Zentralbl Chir 2007; 132(4): 322-327
DOI: 10.1055/s-2007-981200
Originalarbeiten und Übersichten

© Georg Thieme Verlag Stuttgart · New York

Das hepatozelluläre Karzinom: alternative Therapiestrategien

The Hepatocellular Carcinoma: Alternative Therapeutical StrategiesH. C. Spangenberg1 , R. Thimme1 , L. Mohr1 , H. E. Blum1
  • 1Abteilung Innere Medizin II, Medizinische Universitätsklinik, Albert-Ludwigs-Universität Freiburg
Further Information

Publication History

Publication Date:
27 August 2007 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Das hepatozelluläre Karzinom (HCC) ist weltweit einer der häufigsten malignen Tumoren mit steigender Inzidenz auch in westlichen Ländern. Unbehandelt ist die Prognose außerordentlich ungünstig. Zur Therapie des HCCs stehen chirurgische und nicht-chirurgische Verfahren zur Verfügung. Resektion und in ausgewählten Fällen die Lebertransplantation sind die einzigen potenziell kurativen Therapieverfahren. Nicht-chirurgische Therapiemöglichkeiten sind lokal-interventionelle und transarterielle Verfahren. Eine Reihe von alternativen Therapiestrategien wie die medikamentöse Therapie mit antiangiogenetischen, antiproliferativen oder antiinflammatorischen Substanzen, Immuntherapeutika, gentherapeutische Ansätze und die interne bzw. externe Bestrahlung werden derzeit auf ihre Wirksamkeit untersucht, das Überleben bzw. das Rezidiv-freie Überleben der Patienten mit HCC zu verlängern. Diese Arbeit soll einen Überblick über die aktuellen alternativen Therapiemöglichkeiten beim HCC geben.

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in some areas of the world. The prognosis of HCC patients is generally very poor with a 5-year survival rate of less than 5 %. Therapeutic strategies include surgery (resection or liver transplantation) and non-surgical interventions, such as percutaneous ethanol injection or radiofrequency thermal ablation as well as transarterial embolization or chemoembolization. Therefore, the development and evaluation of novel HCC treatment strategies such as the use of antiangiogenic, antiproliferative or antiinflammatoric drugs, immune therapeuticals, gene therapy and internal or external radiation are of utmost importance. This review should give an overview of possible alternative therapies in HCC treatment.

Schlüsselwörter

hepatozelluläres Karzinom - Immuntherapie - Gentherapie - Antiangiogenese - medikamentöse Therapie

Key words

hepatocellular carcinoma - immune therapy - gene therapy - antiangiogenesis - drug therapy

Literatur

  • 1 Abou-Alfa G K, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian N S, Feit K, Ackerman J, De Jager R L, Eckhardt S G, O'Reilly E M. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.  J Clin Oncol. 2006;  24 4441-4447
    CrossrefPubMedGoogle Scholar
  • 2 Adams J, Palombella V J, Elliott P J. Proteasome inhibition: a new strategy in cancer treatment.  Invest New Drugs. 2000;  18 109-121
    CrossrefPubMedGoogle Scholar
  • 3 Becker G, Allgaier H P, Olschewski M, Zahringer A, Blum H E. HECTOR Study Group . Related Articles, Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.  Hepatology. 2007;  45 9-15
    CrossrefPubMedGoogle Scholar
  • 4 Bergsland E K. Molecular mechanisms underlying the development of hepatocellular carcinoma.  Semin Oncol. 2001;  28 521-531
    CrossrefPubMedGoogle Scholar
  • 5 Block A, Chen S H, Kosai K, Finegold M, Woo S L. Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: regression of hepatic metastasis of pancreatic tumors.  Pancreas. 1997;  15 25-34
    PubMedGoogle Scholar
  • 6 Blum H E. Molecular targets for prevention of hepatocellular carcinoma.  Dig Dis. 2002;  20 81-90
    CrossrefPubMedGoogle Scholar
  • 7 Bosch F X, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends.  Gastroenterology. 2004;  127 S5-S16
    CrossrefPubMedGoogle Scholar
  • 8 Bruix J, Sherman M. Management of hepatocellular carcinoma.  Hepatology. 2005;  42 1208-1236
    CrossrefPubMedGoogle Scholar
  • 9 Butterfield L H, Koh A, Meng W, Vollmer C M, Ribas A, Dissette V, Lee E, Glaspy J A, McBride W H, Economou J S. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein.  Cancer Res. 1999;  59 3134-3142
    PubMedGoogle Scholar
  • 10 Butterfield L H, Meng W S, Koh A, Vollmer C M, Ribas A, Dissette V, Faull K, Glaspy J A, McBride W H, Economou J S. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.  J Immunol. 2001;  166 5300-5308
    PubMedGoogle Scholar
  • 11 Butterfield L H, Ribas A, Dissette V B, Lee Y, Yang J Q, De la Rocha P, Duran S D, Hernandez J, Seja E, Potter D M, McBride W H, Finn R, Glaspy J A, Economou J S. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides.  Clin Cancer Res. 2006;  12 2817-2825
    CrossrefPubMedGoogle Scholar
  • 12 Butterfield L H, Ribas A, Meng W S, Dissette V, Amarnani S, Vu H T, Seja E, Todd K, Glaspy J A, McBride W H, Economou J S. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer.  Clin Cancer Res. 2003;  9 5902-5908
    PubMedGoogle Scholar
  • 13 Cantz T, Ott M, Kubicka S, Manns M P. [Gene and immunotherapy of liver diseases].  Internist (Berl). 2001;  42 1357-1362 1364-1365
    CrossrefPubMedGoogle Scholar
  • 14 Caruso Y, Panis M, Gagandeep S, Houssin D, Salzmann J L, Klatzmann D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene.  Proc Natl Acad Sci USA. 1993;  90 7024-7028
    PubMedGoogle Scholar
  • 15 Chenivesse X, Franco D, Brechot C. MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis.  J Hepatol. 1993;  18 168-172
    CrossrefPubMedGoogle Scholar
  • 16 El-Serag H B, Mason A C, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States.  Hepatology. 2001;  33 62-65
    CrossrefPubMedGoogle Scholar
  • 17 Elba S, Giannuzzi V, Misciagna G, Manghisi O G. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma.  Ital J Gastroenterol. 1994;  26 66-68
    PubMedGoogle Scholar
  • 18 Engstrom P F, Levin B, Moertel C G, Schutt A. A phase II trial of tamoxifen in hepatocellular carcinoma.  Cancer. 1990;  65 2641-2643
    CrossrefPubMedGoogle Scholar
  • 19 Farinati F, Salvagnini M, de Maria N, Fornasiero A, Chiaramonte M, Rossaro L, Naccarato R. Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen.  J Hepatol. 1990;  11 297-301
    CrossrefPubMedGoogle Scholar
  • 20 Fuchs C S, Clark J W, Ryan D P, Kulke M H, Kim H, Earle C C, Vincitore M, Mayer R J, Stuart K E. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma.  Cancer. 2002;  94 3186-3191
    CrossrefPubMedGoogle Scholar
  • 21 Hayashi N, Yamamoto H, Hiraoka N, Dono K, Ito Y, Okami J, Kondo M, Nagano H, Umeshita K, Sakon M, Matsuura N, Nakamori S, Monden M. Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm.  Hepatology. 2001;  34 638-650
    CrossrefPubMedGoogle Scholar
  • 22 Hegewisch-Becker S, Sterneck M, Schubert U, Rogiers X, Guerniciolini R, Pierce J E, Hossfeld D K. Phase I/II trial of bortezomib in patients with unresectable hepatocellular carcinoma.  Proc Am Soc Clin Oncol. 2004;  334 ,  (Abstract 4089)
    PubMedGoogle Scholar
  • 23 Hisaka T, Yano H, Haramaki M, Utsunomiya I, Kojiro M. Expressions of epidermal growth factor family and its receptor in hepatocellular carcinoma cell lines: relationship to cell proliferation.  Int J Oncol. 1999;  14 453-460
    PubMedGoogle Scholar
  • 24 Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara K, Ueki T, Hirano T, Yamamoto H, Fujimoto J, Okamoto J, Hayashi N, Hori M. Activation of mitogen-activated protein kinases / extracellular signal-regulated kinases in human hepatocellular carcinoma.  Hepatology. 1998;  27 951-958
    CrossrefPubMedGoogle Scholar
  • 25 Iwashita Y, Tahara K, Goto S, Sasaki A, Kai S, Seike M, Chen C L, Kawano K, Kitano S. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer.  Cancer Immunol Immunother. 2003;  52 155-161
    PubMedGoogle Scholar
  • 26 Jin-no K, Tanimizu M, Hyodo I, Nishikawa Y, Hosokawa Y, Endo H, Doi T, Mandai K, Ishitsuka H. Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients.  Cancer. 1998;  82 1260-1267
    CrossrefPubMedGoogle Scholar
  • 27 Jung Y J, Lee K H, Choi D W, Han C J, Jeong S H, Kim K C, Oh J W, Park T K, Kim C M. Reciprocal expressions of cyclin E and cyclin D1 in hepatocellular carcinoma.  Cancer Lett. 2001;  168 57-63
    CrossrefPubMedGoogle Scholar
  • 28 Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos O N. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.  Gut. 1998;  42 442-447
    CrossrefPubMedGoogle Scholar
  • 29 Kuang M, Peng B G, Lu M D, Liang L J, Huang J F, He Q, Hua Y P, Totsuka S, Liu S Q, Leong K W, Ohno T. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma.  Clin Cancer Res. 2004;  10 1574-1579
    CrossrefPubMedGoogle Scholar
  • 30 Kubicka S, Rudolph K L, Tietze M K, Lorenz M, Manns M. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas.  Hepatogastroenterology. 2001;  48 783-789
    PubMedGoogle Scholar
  • 31 Ladhams A, Schmidt C, Sing G, Butterworth L, Fielding G, Tesar P, Strong R, Leggett B, Powell L, Maddern G, Ellem K, Cooksley G. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells.  J Gastroenterol Hepatol. 2002;  17 889-896
    CrossrefPubMedGoogle Scholar
  • 32 Lin D Y, Lin S M, Liaw Y F. Non-surgical treatment of hepatocellular carcinoma.  J Gastroenterol Hepatol. 1997;  12 S319-S328
    CrossrefPubMedGoogle Scholar
  • 33 Llovet J M, Burroughs A, Bruix J. Hepatocellular carcinoma.  Lancet. 2003;  362 1907-1917
    CrossrefPubMedGoogle Scholar
  • 34 LLovet J, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, Poulin-Costello M, Moscovici M, Voliotis D, Bruix J. for the SHARP investigators study group . Randomized phase III trial of sorafenib versus plazebo in patients with advanced hepatocellular carcinoma.  J Clin Oncol. 2007;  25 18 S, LBA 1
    PubMedGoogle Scholar
  • 35 Lozano R D, Patt T Z, Hassan M M. Oral capecitabine for the treatment of hepatobiliary cancers.  Proc Am Soc Clin Oncol. 2000;  264 ,  (Abstract 1025)
    PubMedGoogle Scholar
  • 36 Luo G, Huang S, Xie X, Stockert E, Chen Y T, Kubuschok B, Pfreundschuh M. Expression of cancer-testis genes in human hepatocellular carcinomas.  Cancer Immun. 2002;  2 11
    PubMedGoogle Scholar
  • 37 Lygidakis N J, Kosmidis P, Ziras N, Parissis J, Kyparidou E. Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem.  J Interferon Cytokine Res. 1995;  15 467-472
    PubMedGoogle Scholar
  • 38 Martinez Cerezo F J, Tomas A, Donoso L, Enriquez J, Guarner C, Balanzo J, Martinez Nogueras A, Vilardell F. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma.  J Hepatol. 1994;  20 702-706
    CrossrefPubMedGoogle Scholar
  • 39 McKillop I H, Schmidt C M, Cahill P A, Sitzmann J V. Altered expression of mitogen-activated protein kinases in a rat model of experimental hepatocellular carcinoma.  Hepatology. 1997;  26 1484-1491
    CrossrefPubMedGoogle Scholar
  • 40 Miura H, Miyazaki T, Kuroda M, Oka T, Machinami R, Kodama T, Shibuya M, Makuuchi M, Yazaki Y, Ohnishi S. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma.  J Hepatol. 1997;  27 854-861
    CrossrefPubMedGoogle Scholar
  • 41 Murray C J, Lopez A D. Mortality by cause for eight regions of the world: Global Burden of Disease Study.  Lancet. 1997;  349 1269-1276
    CrossrefPubMedGoogle Scholar
  • 42 Nakamoto Y, Guidotti L G, Kuhlen C V, Fowler P, Chisari F V. Immune pathogenesis of hepatocellular carcinoma.  J Exp Med. 1998;  188 341-350
    CrossrefPubMedGoogle Scholar
  • 43 Nakamoto Y, Kaneko S, Fan H, Momoi T, Tsutsui H, Nakanishi K, Kobayashi K, Suda T. Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy.  J Exp Med. 2002;  196 1105-1111
    CrossrefPubMedGoogle Scholar
  • 44 Nowak A K, Stockler M R, Chow P K, Findlay M. Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review.  Cancer. 2005;  103 1408-1414
    CrossrefPubMedGoogle Scholar
  • 45 Ozturk M. Genetic aspects of hepatocellular carcinogenesis.  Semin Liver Dis. 1999;  19 235-242
    PubMedGoogle Scholar
  • 46 Patt Y Z, Hassan M M, Lozano R D, Waugh K A, Hoque A M, Frome A I, Lahoti S, Ellis L, Vauthey J N, Curley S A, Schnirer L, Raijman I. Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer.  Clin Cancer Res. 2001;  7 3375-3380
    PubMedGoogle Scholar
  • 47 Peng S Y, Chou S P, Hsu H C. Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma.  J Hepatol. 1998;  29 281-289
    CrossrefPubMedGoogle Scholar
  • 48 Philip A, Mahoney M R, Allmer C, Thomas J, Pitot H C, Kim G, Donehower R C, Fitch T, Picus J, Erlichman C. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.  J Clin Oncol. 2005;  23 6657-6663
    CrossrefPubMedGoogle Scholar
  • 49 Rabe C, Pilz T, Allgaier H P, Halm U, Strasser C, Wettstein M, Sauerbruch T, Caselmann W H. [Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide.].  Z Gastroenterol. 2002;  40 395-400
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Reinisch W, Holub M, Katz A, Herneth A, Lichtenberger C, Schoniger-Hekele M, Waldhoer T, Oberhuber G, Ferenci P, Gangl A, Mueller C. Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma.  J Immunother. 2002;  25 489-499
    CrossrefPubMedGoogle Scholar
  • 51 Reubi J C, Zimmermann A, Jonas S, Waser B, Neuhaus P, Laderach U, Wiedenmann B. Regulatory peptide receptors in human hepatocellular carcinomas.  Gut. 1999;  45 766-774
    PubMedGoogle Scholar
  • 52 Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, Benito A, Larrache J, Pueyo J, Subtil J C, Olague C, Sola J, Sadaba B, Lacasa C, Melero I, Qian C, Prieto J. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.  J Clin Oncol. 2004;  22 1389-1397
    CrossrefPubMedGoogle Scholar
  • 53 Schwartz J D, Schwartz M, Goldman J, Lehrer D, Coll D, Kinkabwala M, Wadler S. Bevacizumab in hepatocellular carcinoma in patients without metastasis and without invasion of the portal vein.  Proc Am Soc Clin Oncol. 2005;  35 ,  (Abstract 134)
    PubMedGoogle Scholar
  • 54 Shah M A, Kortnasky J Gonen M, Drobjnak M, Kenemy N, Saltz L B, Weyerbacher A, Lefkonitz R, Kelson D P, Schwartz G K. Mature results of a phase I study of irinotecan and Flavopirol: a clinically and biologically active regimen.  Proc Am Soc Clin Oncol. 2003;  262 ,  (Abstract 1051)
    PubMedGoogle Scholar
  • 55 Simonetti R G, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials.  Ann Oncol. 1997;  8 117-136
    CrossrefPubMedGoogle Scholar
  • 56 Soini Y, Virkajarvi N, Raunio H, Paakko P. Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis.  J Clin Pathol. 1996;  49 470-473
    PubMedGoogle Scholar
  • 57 Strumberg D, Richly H, Hilger R A, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase C G, Schwartz B, Awada A, Voigtmann R, Scheulen M E, Seeber S. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.  J Clin Oncol. 2005;  23 965-972
    PubMedGoogle Scholar
  • 58 Suzuki K, Hayashi N, Miyamoto Y, Yamamoto M, Ohkawa K, Ito Y, Sasaki Y, Yamaguchi Y, Nakase H, Noda K, Enomoto N, Arai K, Yamada Y, Yoshihara H, Tujimura T, Kawano K, Yoshikawa K, Kamada T. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma.  Cancer Res. 1996;  56 3004-3009
    PubMedGoogle Scholar
  • 59 Tahara K, Mori M, Sadanaga N, Sakamoto Y, Kitano S, Makuuchi M. Expression of the MAGE gene family in human hepatocellular carcinoma.  Cancer. 1999;  85 1234-1240
    CrossrefPubMedGoogle Scholar
  • 60 Takayama T, Makuuchi M, Sekine T, Terui S, Shiraiwa H, Kosuge T, Yamazaki S, Hasegawa H, Suzuki K, Yamagata M. Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary report.  Cancer. 1991;  68 2391-2396
    PubMedGoogle Scholar
  • 61 Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.  Lancet. 2000;  356 802-807
    CrossrefPubMedGoogle Scholar
  • 62 Thomas M B, Dutta A, Brown T, Charnsangavej C, Rashid A, Hoff P M, Dancey J, Abbruzzese J L. Phase II open-label study of OS!-774 in unresectable hepatocellular carcinoma.  Proc Am Soc Clin Oncol. 2005;  321 ,  (Abstract 4038)
    PubMedGoogle Scholar
  • 63 Thorgeirsson S S. Hunting for tumor suppressor genes in liver cancer.  Hepatology. 2003;  37 739-741
    CrossrefPubMedGoogle Scholar
  • 64 Yang T S, Lin Y C, Chen J S, Wang H M, Wang C H. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.  Cancer. 2000;  89 750-756
    CrossrefPubMedGoogle Scholar
  • 65 Yuen M F, Poon R T, Lai C L, Fan S T, Lo C M, Wong K W, Wong W M, Wong B C. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.  Hepatology. 2002;  36 687-691
    CrossrefPubMedGoogle Scholar
  • 66 Zerbini A, Pilli M, Soliani P, Ziegler S, Pelosi G, Orlandini A, Cavallo C, Uggeri J, Scandroglio R, Crafa P, Spagnoli G C, Ferrari C, Missale G. Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+ cells in patients with hepatocellular carcinoma.  J Hepatol. 2004;  40 102-109
    PubMedGoogle Scholar
  • 67 Zhu A X, Sahani D, Norden-Zfoni N, Holalkere N S, Blaszkowsky L, Ryan D P, Clark J W, Taylor K, Heymach J V, Stuart K. A phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with hepatocellular carcinoma.  Proc Am Soc Clin Oncol. 2005;  331 , (Abstract 4120)
    PubMedGoogle Scholar

PD Dr. H. C. Spangenberg

Abteilung Innere Medizin II · Medizinische Universitätsklinik · Albert-Ludwigs-Universität Freiburg

Hugstetter Straße 55

79106 Freiburg

Email: spangenberg@med1.ukl.uni-freiburg.de

      >